Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 10 August 2025 | Viewed by 3102

Special Issue Editors


E-Mail Website
Guest Editor
Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea
Interests: alternative cell death mode; cancer cell metabolism; natural product; tumor microenvironment; immune mechanism; cellular basis of cancer therapy resistance; small molecule-based therapeutics

E-Mail Website
Guest Editor
1. National University Cancer Science Institute, National University Health System (NUHS), Singapore, Singapore
2. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Interests: regulation of cell death signaling in cancer cells; reactive oxygen species and cell fate; Bcl-2 family and mitochondrial metabolism; protein phosphatase PP2A and cancer; autophagy and cancer; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The intricate interplay between alternative cell death modes and their impact on cancer stem cells (CSCs) opens new opportunities in the realm of cancer research. In this Special Issue of Cancers, titled "Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies", we aim to explore the multifaceted roles of unconventional cell death pathways in shaping CSC biology.

Traditional apoptosis has been extensively studied, but emerging evidence suggests the involvement of non-apoptotic cell death modes like necroptosis, ferroptosis, and autophagy in modulating the fate of CSCs. Understanding how these alternative cell death mechanisms intersect with CSC regulation holds great promise for advancing our comprehension of tumorigenesis.

We invite original research articles and reviews delving into the intricate connections between alternative cell death modes and CSC dynamics. Contributions may span investigations using various cancer models, encompassing in vitro and in vivo approaches across diverse cancer types. By assembling studies exploring the intersection of unconventional cell death and CSC biology, we hope to gain deeper insights into innovative therapeutic avenues for combating cancer.

Join us in exploring cutting-edge research, aiming to unravel the complex relationships between alternative cell death modes and cancer stem cells, ultimately paving the way for novel therapeutic strategies.

Dr. Mun-Ock Kim
Prof. Dr. Shazib Pervaiz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer stem cell
  • alternative cell death mode
  • tumor microenvironment
  • immune mechanism
  • cellular basis of cancer therapy resistance
  • cellular transformation
  • small-molecule-based therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 6785 KiB  
Review
Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy
by Dong Oh Moon
Cancers 2024, 16(17), 2958; https://doi.org/10.3390/cancers16172958 - 24 Aug 2024
Viewed by 1246
Abstract
The analysis begins with a detailed examination of the gene expression and protein structure of KIF20A, highlighting its interaction with critical cellular components that influence key processes such as Golgi membrane transport and mitotic spindle assembly. The primary focus is on the development [...] Read more.
The analysis begins with a detailed examination of the gene expression and protein structure of KIF20A, highlighting its interaction with critical cellular components that influence key processes such as Golgi membrane transport and mitotic spindle assembly. The primary focus is on the development of specific KIF20A inhibitors, detailing their roles and the challenges encountered in enhancing their efficacy, such as achieving specificity, overcoming tumor resistance, and optimizing delivery systems. Additionally, it delves into the prognostic value of KIF20A across multiple cancer types, emphasizing its role as a novel tumor-associated antigen, which lays the groundwork for the development of targeted peptide vaccines. The therapeutic efficacy of these vaccines as demonstrated in recent clinical trials is discussed. Future directions are proposed, including the integration of precision medicine strategies to personalize treatments and the use of combination therapies to improve outcomes. By concentrating on the significant potential of KIF20A as both a direct target for inhibitors and an antigen in cancer vaccines, this review sets a foundation for future research aimed at harnessing KIF20A for effective cancer treatment. Full article
Show Figures

Figure 1

23 pages, 3097 KiB  
Review
Deciphering the Role of BCAR3 in Cancer Progression: Gene Regulation, Signal Transduction, and Therapeutic Implications
by Dong Oh Moon
Cancers 2024, 16(9), 1674; https://doi.org/10.3390/cancers16091674 - 26 Apr 2024
Viewed by 1518
Abstract
This review comprehensively explores the gene BCAR3, detailing its regulation at the gene, mRNA, and protein structure levels, and delineating its multifunctional roles in cellular signaling within cancer contexts. The discussion covers BCAR3’s involvement in integrin signaling and its impact on cancer cell [...] Read more.
This review comprehensively explores the gene BCAR3, detailing its regulation at the gene, mRNA, and protein structure levels, and delineating its multifunctional roles in cellular signaling within cancer contexts. The discussion covers BCAR3’s involvement in integrin signaling and its impact on cancer cell migration, its capability to induce anti-estrogen resistance, and its significant functions in cell cycle regulation. Further highlighted is BCAR3’s modulation of immune responses within the tumor microenvironment, a novel area of interest that holds potential for innovative cancer therapies. Looking forward, this review outlines essential future research directions focusing on transcription factor binding studies, isoform-specific expression profiling, therapeutic targeting of BCAR3, and its role in immune cell function. Each segment builds towards a holistic understanding of BCAR3′s operational mechanisms, presenting a critical evaluation of its therapeutic potential in oncology. This synthesis aims to not only extend current knowledge but also catalyze further research that could pivotally influence the development of targeted cancer treatments. Full article
Show Figures

Figure 1

Back to TopTop